📊 VRCA Key Takeaways
Is Verrica Pharmaceuticals Inc. (VRCA) a Good Investment?
Verrica demonstrates impressive revenue growth of 370% YoY and maintains a solid cash position with zero long-term debt, indicating near-term financial viability. However, the company is deeply unprofitable with operating losses of $9.7M on just $5M revenue and negative free cash flow of $9.2M, providing limited runway without demonstrated progress toward profitability or achievement of major commercialization milestones.
Verrica Pharmaceuticals Inc. Key Strengths (VRCA)
- Strong top-line revenue growth of 370% YoY demonstrates early market traction and product acceptance
- Solid cash position of $20.6M representing 53% of total assets with zero long-term debt reduces financial distress risk
- Healthy liquidity ratios (current 2.10x, quick 1.98x) provide adequate short-term financial flexibility
VRCA Stock Risks: Verrica Pharmaceuticals Inc. Investment Risks
- Deeply unprofitable with operating losses of $9.7M exceeding revenue of $5M by 194%, indicating unsustainable unit economics
- Negative free cash flow of $9.2M with approximately 2 years of cash runway at current burn rate without profitability inflection
- Very small absolute revenue base from nascent commercialization makes path to sustainable profitability unclear and subject to execution risk
Key Metrics to Watch
- Operating cash flow trajectory toward break-even and timeline to profitability
- Revenue growth sustainability, product adoption rates, and gross margin expansion
- Cash burn rate and timing of next financing event or need for capital raise
Verrica Pharmaceuticals Inc. (VRCA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.10x current ratio provides a solid financial cushion.
VRCA Profit Margin, ROE & Profitability Analysis
VRCA vs Healthcare Sector: How Verrica Pharmaceuticals Inc. Compares
How Verrica Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Verrica Pharmaceuticals Inc. Stock Overvalued? VRCA Valuation Analysis 2026
Based on fundamental analysis, Verrica Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Verrica Pharmaceuticals Inc. Balance Sheet: VRCA Debt, Cash & Liquidity
VRCA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Verrica Pharmaceuticals Inc.'s revenue has declined by 37% over the 5-year period, indicating business contraction. The most recent EPS of $-14.78 indicates the company is currently unprofitable.
VRCA Revenue Growth, EPS Growth & YoY Performance
VRCA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $5.2M | $204.0K | $0.02 |
| Q1 2025 | $3.4M | -$9.7M | $-0.10 |
| Q3 2024 | -$1.8M | -$6.6M | $-0.49 |
| Q2 2024 | $182.0K | -$6.6M | $-0.24 |
| Q1 2024 | $37.0K | -$6.6M | $-0.15 |
| Q3 2023 | $2.9M | $83.0K | $0.00 |
| Q2 2023 | $182.0K | -$6.6M | $-0.24 |
| Q1 2023 | $37.0K | -$6.6M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Verrica Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
VRCA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Verrica Pharmaceuticals Inc. (CIK: 0001660334)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 9, 2026 | 4 | xslF345X06/form4-06092026_040606.xml | View → |
| Jun 9, 2026 | 4 | xslF345X06/form4-06092026_040603.xml | View → |
| Jun 9, 2026 | 4 | xslF345X06/form4-06092026_040601.xml | View → |
| Jun 9, 2026 | 4 | xslF345X06/form4-06092026_040614.xml | View → |
| Jun 9, 2026 | 4 | xslF345X06/form4-06092026_040612.xml | View → |
❓ Frequently Asked Questions about VRCA
What is the AI rating for VRCA?
Verrica Pharmaceuticals Inc. (VRCA) has an AI grade of B with 58% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VRCA's key strengths?
Claude: Strong top-line revenue growth of 370% YoY demonstrates early market traction and product acceptance. Solid cash position of $20.6M representing 53% of total assets with zero long-term debt reduces financial distress risk.
What are the risks of investing in VRCA?
Claude: Deeply unprofitable with operating losses of $9.7M exceeding revenue of $5M by 194%, indicating unsustainable unit economics. Negative free cash flow of $9.2M with approximately 2 years of cash runway at current burn rate without profitability inflection.
What is VRCA's revenue and growth?
Verrica Pharmaceuticals Inc. reported revenue of $5.0M.
Does VRCA pay dividends?
Verrica Pharmaceuticals Inc. does not currently pay dividends.
Where can I find VRCA SEC filings?
Official SEC filings for Verrica Pharmaceuticals Inc. (CIK: 0001660334) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VRCA's EPS?
Verrica Pharmaceuticals Inc. has a diluted EPS of $-0.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VRCA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Verrica Pharmaceuticals Inc. has a B grade with 58% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VRCA stock overvalued or undervalued?
Valuation metrics for VRCA: ROE of -60.3% (sector avg: 15%), net margin of -192.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VRCA's AI grade for 2026?
Our dual AI analysis gives Verrica Pharmaceuticals Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VRCA's free cash flow?
Verrica Pharmaceuticals Inc.'s operating cash flow is $-9.2M, with capital expenditures of $0.0. FCF margin is -182.4%.
How does VRCA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -192.8% (avg: 12%), ROE -60.3% (avg: 15%), current ratio 2.10 (avg: 2).